News and Press Releases
Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease
Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4 VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025
PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial
Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries Safety and functionality data for the updated Liquid Biopsy System supports continuation of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease
Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 -- Alderley Park, UK --...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK
Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...
Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025
CPHI Milan analysis ‘Lombardy the best location for pharma manufacturing in Europe’
Report predicts significant growth for Lombardy’s pharma industry in 2025 as event directly contributes more than €120m to region 3 October 2024 – Milan, Italy – The global pharma industry...
Category: Pharmaceutical
Posted: October 3, 2024
PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease
Project evaluated small molecules against novel target in coronary artery disease discovered by PlaqueTec Bespoke cell-based assay developed by RxCelerate to test small molecules predicted to bind candidate target. 18...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 18, 2024
CPHI Annual Report 2024: CPHI Milan Report predicts BLA and Tides approvals will surpass small molecules within the next three years
Bio and Tides predicted to be the fastest growing modality for CDMOs over the next five years 12 September 2024 – Milan, Italy – Ahead of CPHI Milan – the...
Category: Pharmaceutical
Posted: September 12, 2024
Mission Therapeutics awarded $5.2m from The Michael J Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease Marks latest step in Mission’s relationship with The Michael J Fox Foundation (MJFF), after...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
Exonate appoints Dr Rafiq Hasan as Non-Executive Director
Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board 28 May 2024 -- Cambridgeshire, UK -- Exonate, a biotechnology company developing...
Category: Biotechnology, Pharmaceutical
Posted: May 28, 2024
PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec 14 May 2024 -- Cambridge, UK -- PlaqueTec, a company identifying endotype-specific biomarkers...
Category: Biotechnology, Drug Discovery
Posted: May 14, 2024
PlaqueTec closes $8m equity financing
The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support ongoing BIOPATTERN trial and build BIOCARTA database to transform...
Category: Biotechnology, Other, Pharmaceutical
Posted: April 30, 2024
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, Germany, researchers from the Mayo Clinic in Rochester, USA and HepaRegeniX HRX-215 proved to be safe and well...
Category: Biotechnology
Posted: March 15, 2024
PlaqueTec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood
Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN...
Category: Biotechnology
Posted: January 23, 2024
PlaqueTec recruits first ten patients in BIOPATTERN trial
Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...
Category: Clinical Trials
Posted: November 29, 2023
